SCHEMBL30643111

SCHEMBL30643111

CN(C)C(=O)c1cc2cnc(Cl)nc2n1-c1ccc2c(c1)CCC2N(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 16/20 0.41
CCND1 P24385 8/20 0.41
CDK1 P06493 1/20 0.38
F10 P00742 3/20 0.37
ACHE P22303 1/20 0.36
CDK2 P24941 2/20 0.36
CCND3 P30281 2/20 0.36
CDK6 Q00534 2/20 0.36
GAK O14976 1/20 0.36
CCNT1 O60563 1/20 0.36
CCNA2 P20248 1/20 0.36
FECH P22830 1/20 0.36
CDK9 P50750 1/20 0.36
CDK16 Q00536 1/20 0.36
MAP3K1 Q13233 1/20 0.36
CAMK2G Q13555 1/20 0.36
CAMK2D Q13557 1/20 0.36
Q6ZSR9 Q6ZSR9 1/20 0.36
PRKD2 Q9BZL6 1/20 0.36
SIK2 Q9H0K1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26637834 1.00 CDK4 (0.41) CDK4CCND1CDK1F10ACHE
SCHEMBL26638064 0.94 CDK4 (0.41) CDK4CCND1CDK1CDK2CCND3
SCHEMBL30643094 0.94 CDK4 (0.41) CDK4CCND1CDK1CDK2CCND3
SCHEMBL30643122 0.84 CDK4 (0.39) CDK4CCND1CDK1CDK2CCND3
SCHEMBL30643129 0.83 CDK4 (0.38) CDK4CCND1CDK1CDK2CCND3
SCHEMBL30643114 0.81 CDK4 (0.37) CDK4CCND1CDK1CDK2CCND3
SCHEMBL30643140 0.79 CDK4 (0.42) CDK4CCND1CDK1CCND3CDK6
SCHEMBL30643128 0.78 CDK4 (0.39) CDK4CCND1CDK1CDK2CCND3
SCHEMBL30643096 0.78 CDK4 (0.41) CDK4CCND1CDK1CDK2CCND3
SCHEMBL30643105 0.77 CDK4 (0.41) CDK4CCND1CDK2CCND3CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4519267-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene, Ltd. (KY) 2025-03-12 EP disclosed
US-20250066372-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-02-27 US disclosed
CN-119156389-A Heterocyclic compounds, compositions thereof and methods of treatment thereof 百济神州有限公司 2024-12-17 CN disclosed
WO-2023213271-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066372-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CDK1, CDK2, CDK4 CDK4 3/4885CCND1 69/4885CDK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.